Ivan Kairatov is a leading voice in biopharmaceutical innovation, bringing years of experience in metabolic research and the development of disruptive medical technologies. In this discussion, we explore the recent landmark approval of an oral semaglutide tablet by the UK’s Medicines and Healthcare products Regulatory Agency, marking a historic shift in obesity care. Our conversation covers the practical advantages of moving away from injectable treatments, the impressive weight-loss percentages observed in the OASIS 4 clinical trials, the management of common gastrointestinal side effects, and the broader impact this daily pill will have on the 15 million people living with obesity in the United Kingdom.
How does the transition from a traditional injectable format to a daily 25mg oral dose change the treatment landscape for patients who have historically struggled with the logistics of GLP-1 therapies?
The move to an oral pill is a truly landmark moment because it removes the significant psychological and physical barrier that needles often present to the general public. For many of the 15 million people living with obesity in the UK, the daily habit of taking a tablet fits much more naturally into a morning routine than a weekly injection. This flexibility allows for a greater sense of autonomy, where patients can manage their health without the specialized storage or the clinical feeling of disposal requirements that come with syringes. It is not merely a matter of convenience; it is about providing a first-of-its-kind alternative that could encourage those who were previously therapy-hesitant to finally seek the medical support they need for long-term weight management.
When we look at the OASIS 4 trial data, specifically the difference between a 14% weight loss in general treatment and a nearly 17% loss among strictly adherent patients, what does this tell us about the drug’s clinical potential?
The data from the 307 adults in the OASIS 4 study is quite compelling because it shows a clear, powerful response over a 64-week period when combined with lifestyle modifications. While the placebo group saw only about a 2.4% reduction, those taking the 25mg semaglutide tablets achieved a substantial 13.6% weight loss under broader evaluation conditions. What is even more striking is that for those who followed the protocol exactly as prescribed, that number jumped to 16.6%, which is almost triple the results seen in the control group. These figures prove that oral delivery does not mean sacrificing the clinical potency we have come to expect from the injectable versions of this hormone mimic.
With roughly 74% of participants reporting gastrointestinal side effects like nausea or vomiting, how should clinicians and patients manage these challenges to ensure long-term success?
It is true that gastrointestinal issues were reported by nearly three-quarters of the oral group, but we have to put that into perspective by comparing it to the 42.2% reported in the placebo group. Most of these symptoms, including nausea and diarrhea, are generally mild-to-moderate and transient, meaning they tend to fade as the body becomes accustomed to the medication. Importantly, only about 6.9% of participants in the OASIS 4 trial had to stop treatment entirely due to adverse events, which is a rate very consistent with what we have seen in previous injectable trials. Educating patients that these sensory discomforts are likely temporary is a vital action for clinicians to ensure patients reach their ultimate health goals without becoming discouraged in the first month.
As the first country in Europe to approve this oral treatment, how significant is this move for the UK’s broader strategy in tackling the obesity epidemic and its associated comorbidities?
This is a massive win for the UK’s public health infrastructure, placing the country alongside the US and the UAE as a global leader in metabolic innovation. With obesity rates currently at very high levels, the strain on the healthcare system from associated multimorbidity is becoming unsustainable, and we desperately need more options for sustained weight loss. By making this daily pill available as an adjunct to a reduced-calorie diet and increased physical activity, the UK is taking a proactive stance to reach a much larger portion of the eligible population. This approval represents a strategic expansion of care that recognizes we need diverse delivery systems to effectively combat a crisis that affects such a vast number of citizens across the nation.
What is your forecast for the future of oral metabolic treatments in the next five years?
I anticipate that the approval of this daily pill will trigger a rapid shift where oral treatments become the preferred starting point for metabolic care in primary practice. As production scales and more real-world data flows in from the UK, the reliance on refrigerated injectable therapies will likely diminish for the average patient. We are entering an era where managing weight will be handled with the same routine simplicity as managing high blood pressure or cholesterol. Within half a decade, I expect we will see even more refined oral formulations that offer similar efficacy with an even further reduced side-effect profile, significantly lowering the global burden of chronic metabolic disease.
